Johnson & JohnsonJNJ +1.51%85 Days Payable is 126.37 as of Mar. 2026, which is 2% above its 10-year median of 124.18. GuruFocus rates JNJ with a GF Score™ of 85/100 and a GF Value™ of $190.57 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 920 Drug Manufacturers companies, Johnson & Johnson ranks better than 65.98% on this metric.
The historical rank and industry rank for Johnson & Johnson's Days Payable or its related term are showing as below:
JNJ'
s Days Payable Range Over the Past 10 Years
Min: 100.02 Med: 124.18 Max: 160.34
Current: 120.28
During the past 13 years, Johnson & Johnson's highest Days Payable was 160.34. The lowest was 100.02. And the median was 124.18.
JNJ's Days Payable is ranked better than 65.98% of 920
companies
in the Drug Manufacturers industry
Industry Median: 90.835
vs JNJ: 120.28
Johnson & Johnson's Days Payable
increased
from Mar. 2025 (123.14) to Mar. 2026 (126.37).
It may suggest that Johnson & Johnsondelayed paying its suppliers.
Johnson & Johnson Days Payable Related Terms
Johnson & Johnson Days Payable Historical Data
* Premium members only.
The historical data trend for Johnson & Johnson's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - General subindustry, Johnson & Johnson's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Johnson & Johnson Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Johnson & Johnson's Days Payable distribution charts can be found below:
* The bar in red indicates where Johnson & Johnson's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Johnson & Johnson's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Johnson & Johnson (JNJ) has a Days Payable of 126.37 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Johnson & Johnson and its competitors. This is near median its historical median of 124.18. Over the past decade, Johnson & Johnson's Days Payable has ranged from 100.02 to 160.34. According to the industry distribution chart, Johnson & Johnson ranks #313 out of 920 companies in the Drug Manufacturers industry, placing it in the top 34%.
Is Johnson & Johnson's Days Payable too high?
Johnson & Johnson's current Days Payable of 126.37 is near median its 10-year median of 124.18. Over the past 10 years, this metric has ranged from a low of 100.02 to a high of 160.34. The Drug Manufacturers industry median Days Payable is 90.84. Johnson & Johnson's value of 126.37 is 39.1% above this industry median. Based on the distribution chart, Johnson & Johnson ranks #313 out of 920 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Johnson & Johnson has a GF Score™ of 85/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Johnson & Johnson's Days Payable compare to ABBV and MRK?
According to the Drug Manufacturers industry distribution chart, Johnson & Johnson ranks #313 out of 920 companies for Days Payable. This puts Johnson & Johnson in the upper half of its industry. The industry median Days Payable is 90.84. Johnson & Johnson's value of 126.37 is 39.1% above this benchmark. Historically, Johnson & Johnson's own Days Payable has ranged from 100.02 to 160.34 over the past decade. While the company's 10-year median is 124.18 vs. the industry median of 90.84, Johnson & Johnson has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.84, based on 920 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Johnson & Johnson's current Days Payable of 126.37 is 39.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Johnson & Johnson and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Johnson & Johnson's current Days Payable is 126.37, which is near median its own 10-year median of 124.18. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Johnson & Johnson stock overvalued right now?
Based on GuruFocus' analysis, Johnson & Johnson (JNJ) is currently considered Significantly Overvalued. The stock's GF Value™ is $190.57, compared to a current price of $258.51 — trading 35.7% above its estimated fair value. The current Days Payable is 126.37, which is near median its 10-year median of 124.18 and 39.1% above the Drug Manufacturers industry median of 90.84. Johnson & Johnson's overall GF Score™ is 85/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Johnson & Johnson (JNJ), the current Days Payable is 126.37 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Johnson & Johnson (JNJ) Overvalued in 2026?
Based on GuruFocus' analysis, Johnson & Johnson stock appears to be overvalued.
The current stock price of $258.51 is trading 35.7% above its estimated GF Value™ of $190.57.
GuruFocus considers Johnson & Johnson to be Significantly Overvalued.
Key valuation signals for JNJ:
Days Payable: 126.37 (near median its 10-year median of 124.18)
GF Value™: $190.57 vs. price of $258.51 (35.7% above fair value)
Industry Position: 39.1% above the Drug Manufacturers median (#313 of 920)
No single metric tells the full story. See the JNJ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: innovative medicine and medtech. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. After restructurings in 2023-24, the drug division focuses on three main therapeutic areas: immunology, oncology, and neurology. Geographically, just over half of total revenue is generated in the United States.
85GF Score
Get the complete analysis for JNJ
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
JNJ has been successfully added to your 
